Prime Therapeutics’ Clinical Insights is your trusted resource for timely, evidence based perspectives on emerging therapies and managed care strategy. The Summer 2025 issue focuses on metabolic dysfunction–associated steatohepatitis (MASH)—a chronic liver disease affecting over 22 million U.S. adults.

This issue explores:

• Treatment Innovation:
  • FDA approval of Rezdiffra™, the first MASH-specific therapy 
  • GLP-1s like semaglutide showing promise in liver health 
  • Comparative insights and pipeline outlook
• Payer Strategy: 
  • Cost projections and market growth through 2030 
  • Prime’s KeepWell™ solution for whole-person care 
  • Clinical guidance from AASLD, ADA, AGA, and EASL
• Population Health:
  • Risk factors and disparities in MASH prevalence
  • Pediatric and lean MASLD considerations
  • Diagnostic pathways and noninvasive tools

Explore how Prime is helping clients save, simplify, and support in the evolving MASH landscape.